JP2020533301A - インターロイキン−１８バリアントとその利用法 - Google Patents

インターロイキン−１８バリアントとその利用法 Download PDF

Info

Publication number
JP2020533301A
JP2020533301A JP2020513648A JP2020513648A JP2020533301A JP 2020533301 A JP2020533301 A JP 2020533301A JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020533301 A JP2020533301 A JP 2020533301A
Authority
JP
Japan
Prior art keywords
seq
variant
variant polypeptide
amino acid
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533301A5 (OSRAM
Inventor
リング アーロン
リング アーロン
チョウ ティン
チョウ ティン
フィッシャー スザンヌ
フィッシャー スザンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2020533301A publication Critical patent/JP2020533301A/ja
Publication of JP2020533301A5 publication Critical patent/JP2020533301A5/ja
Priority to JP2023133442A priority Critical patent/JP2023157959A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2020513648A 2017-09-06 2018-09-06 インターロイキン−１８バリアントとその利用法 Pending JP2020533301A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133442A JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554605P 2017-09-06 2017-09-06
US62/554,605 2017-09-06
US201862652279P 2018-04-03 2018-04-03
US62/652,279 2018-04-03
PCT/US2018/049648 WO2019051015A1 (en) 2017-09-06 2018-09-06 VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133442A Division JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Publications (2)

Publication Number Publication Date
JP2020533301A true JP2020533301A (ja) 2020-11-19
JP2020533301A5 JP2020533301A5 (OSRAM) 2021-10-14

Family

ID=65517760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513648A Pending JP2020533301A (ja) 2017-09-06 2018-09-06 インターロイキン−１８バリアントとその利用法
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Country Status (13)

Country Link
US (6) US20190070262A1 (OSRAM)
EP (1) EP3678681A4 (OSRAM)
JP (2) JP2020533301A (OSRAM)
KR (1) KR20200066623A (OSRAM)
CN (1) CN111315395A (OSRAM)
AU (2) AU2018330444B2 (OSRAM)
BR (1) BR112020004389A2 (OSRAM)
CA (1) CA3080492A1 (OSRAM)
IL (2) IL305370A (OSRAM)
MX (1) MX2020002542A (OSRAM)
SG (1) SG11202001384TA (OSRAM)
WO (1) WO2019051015A1 (OSRAM)
ZA (1) ZA202307212B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022172944A1 (OSRAM) * 2021-02-10 2022-08-18
WO2023013763A1 (ja) 2021-08-06 2023-02-09 国立大学法人 長崎大学 がんの治療剤

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN115667290A (zh) * 2020-05-12 2023-01-31 再生元制药公司 新型il10激动剂及其使用方法
US20220056091A1 (en) * 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof
KR20230117120A (ko) * 2020-11-02 2023-08-07 심카 아이엘-18, 인크. 인터류킨-18 변이체 및 사용 방법
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
WO2023114829A1 (en) * 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
JP2025508826A (ja) * 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－１８ポリペプチド
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
MX2024011278A (es) 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
WO2023215834A1 (en) * 2022-05-05 2023-11-09 Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. Methods for treating bladder cancer
KR20250046308A (ko) * 2022-08-05 2025-04-02 퓨즈 바이오쎄라퓨틱스 아이엔씨. Il-18 융합 단백질 및 il-18 생산 방법
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
JP2025529313A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド Ｉｌ－１８バリアントポリペプチド
US20240209100A1 (en) * 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240166705A1 (en) * 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins
WO2024120489A1 (en) 2022-12-07 2024-06-13 Guangzhou Virotech Pharmaceutical Co., Ltd. Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
WO2024148241A1 (en) * 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
CN120693345A (zh) * 2023-01-06 2025-09-23 艾利妥 抗il18结合蛋白抗体及其使用方法
AU2024211503A1 (en) * 2023-01-24 2025-07-31 Msd International Business Gmbh Methods and compositions for combination therapy
WO2024251983A1 (en) * 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025015103A1 (en) * 2023-07-10 2025-01-16 The Children's Hospital Of Philadelphia Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
CN120093897A (zh) * 2023-12-04 2025-06-06 广州威溶特医药科技有限公司 Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
CN120189493A (zh) 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025251226A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) * 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
JP2011105737A (ja) * 2003-04-15 2011-06-02 Glaxosmithkline Llc ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2017103088A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
EP1669454A3 (en) * 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP2001266941A (ja) 2000-03-17 2001-09-28 Sony Corp ゲル電解質電池の製造方法
AU7516601A (en) * 2000-06-02 2001-12-17 Susan B Dillon Methods of treating viral diseases with il-18 and il-18 combinations
ATE437234T1 (de) 2000-06-15 2009-08-15 Smithkline Beecham Corp Verfahren zur herstellung eines physiologisch aktiven il-18 polypeptids
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
CA2445049A1 (en) 2001-05-04 2002-11-14 Cornell Research Foundation, Inc. Rapidly cleavable sumo fusion protein expression system for difficult to express proteins
BR0206112A (pt) 2001-10-10 2005-05-10 Centocor Inc Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
US20040023336A1 (en) 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
DE60318014T2 (de) 2002-01-07 2008-11-27 Lifesensors, Inc. Verfahren und zusammensetzungen für die proteinexpression und reinigung
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7253260B2 (en) 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
AU2003280017A1 (en) * 2002-06-27 2004-01-19 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
ATE549353T1 (de) * 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
US7655413B2 (en) 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ES2356154T3 (es) * 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
CN101039696B (zh) 2004-08-20 2011-08-17 史密丝克莱恩比彻姆公司 给药人il-18治疗创伤的方法
WO2006073976A2 (en) 2004-12-30 2006-07-13 Lifesensors, Inc. Compositions, methods, and kits for enhancing protein expression, solubility and isolation
JP2010503680A (ja) 2006-09-14 2010-02-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒトｉｌ−１８による調節ｔ細胞のモジュレーション
JP5469786B2 (ja) 2006-12-29 2014-04-16 ライフセンサーズ、インク． タンパク質の発現増強および精製の方法および組成
CN104888193A (zh) 2007-11-07 2015-09-09 健泰科生物技术公司 用于治疗微生物病症的组合物和方法
WO2009107458A1 (ja) 2008-02-27 2009-09-03 シャープ株式会社 照明装置、表示装置及びテレビ受信装置
US8034910B2 (en) 2008-05-06 2011-10-11 Academia Sinica, Taiwan SUMO fusion protein expression system for producing native proteins
CN101993495B (zh) 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
US9316417B2 (en) 2012-06-29 2016-04-19 Sunpower Corporation Framing system for mounting solar collecting devices
CA2876099A1 (en) 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2015054386A1 (en) 2013-10-08 2015-04-16 Georgia State University Research Foundation, Inc Compositions including il-18 and il-22 and their use in anti-viral therapies
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
JP6912384B2 (ja) 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
ITUA20161992A1 (it) 2016-03-24 2017-09-24 Plico Biotech Inc Sumo e suoi utilizzi
WO2018027155A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
EP3519436A4 (en) 2016-09-30 2020-09-09 Baylor College of Medicine TISSUE-ORIENTED ANTIBODY-BASED GENE THERAPY
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
KR102739572B1 (ko) 2017-03-06 2024-12-10 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
AU2018297248A1 (en) 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
JP2021521877A (ja) 2018-05-04 2021-08-30 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ 宿主細胞タンパク質のレベルが低減した組換えタンパク質の生産
CA3108949A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
AU2019328575B2 (en) 2018-08-30 2024-07-11 Immunitybio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP2022518144A (ja) 2019-01-04 2022-03-14 レパトワー イミューン メディシンズ， インコーポレイテッド 高多様性ペプチドライブラリーを生成する方法およびタンパク質折り畳みを促進する方法
JP7754723B2 (ja) 2019-05-14 2025-10-15 ウェアウルフ セラピューティクス， インコーポレイテッド 分離部分及びその使用方法
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3976068A4 (en) 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
CA3150818A1 (en) 2019-08-13 2021-02-18 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
CA3154771A1 (en) 2019-10-09 2021-04-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cytotoxic t cell resistant tumors
US20220047677A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc. Immune cell function
US20220056091A1 (en) 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof
KR20230117120A (ko) 2020-11-02 2023-08-07 심카 아이엘-18, 인크. 인터류킨-18 변이체 및 사용 방법
US20240197880A1 (en) 2021-04-30 2024-06-20 Cellectis S.A. New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
WO2022260968A1 (en) 2021-06-10 2022-12-15 Chimera Bioengineering, Inc. Compositions and methods for activating natural killer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530432A (ja) * 2001-03-08 2004-10-07 アレス・トレーディング・ソシエテ・アノニム インターロイキン−１８変異体、その産生および使用
JP2011105737A (ja) * 2003-04-15 2011-06-02 Glaxosmithkline Llc ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2017103088A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PROC NATL ACAD SCI, vol. 97(3):1190-5, JPN6022027410, 2000, ISSN: 0005174633 *
PROC NATL ACAD SCI, vol. 98(6):3304-9, JPN6022027413, 2001, ISSN: 0005174632 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022172944A1 (OSRAM) * 2021-02-10 2022-08-18
WO2022172944A1 (ja) * 2021-02-10 2022-08-18 国立大学法人 長崎大学 新規ヒトインターロイキン－１８変異体及びその用途
WO2023013763A1 (ja) 2021-08-06 2023-02-09 国立大学法人 長崎大学 がんの治療剤

Also Published As

Publication number Publication date
IL272635B2 (en) 2024-02-01
ZA202307212B (en) 2024-10-30
JP2023157959A (ja) 2023-10-26
KR20200066623A (ko) 2020-06-10
US20190070262A1 (en) 2019-03-07
RU2020112538A3 (OSRAM) 2022-04-04
EP3678681A4 (en) 2021-07-14
IL272635A (en) 2020-03-31
US20230241172A1 (en) 2023-08-03
US20240325494A1 (en) 2024-10-03
AU2018330444A1 (en) 2020-04-23
CA3080492A1 (en) 2019-03-14
IL272635B1 (en) 2023-10-01
US20230321192A1 (en) 2023-10-12
AU2018330444B2 (en) 2023-08-17
US12403180B2 (en) 2025-09-02
BR112020004389A2 (pt) 2020-09-08
SG11202001384TA (en) 2020-03-30
CN111315395A (zh) 2020-06-19
AU2023266285A1 (en) 2024-01-25
US20250057918A1 (en) 2025-02-20
US12343379B2 (en) 2025-07-01
US20230355714A1 (en) 2023-11-09
IL305370A (en) 2023-10-01
WO2019051015A1 (en) 2019-03-14
RU2020112538A (ru) 2021-10-06
MX2020002542A (es) 2020-07-20
EP3678681A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
JP2023157959A (ja) インターロイキン－１８バリアントとその利用法
US11850276B2 (en) Interleukin-18 variants and methods of use
US12029778B2 (en) Interleukin-18 mimics and methods of use
TW202019971A (zh) 抗間皮素抗體
US20240342246A1 (en) Interleukin-12 variants and methods of use
CN119497718A (zh) 三特异性抗体及其用途
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения
TW202434631A (zh) 抗il-2抗體之使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251212